12:00 AM
Jan 19, 2004
 |  BioCentury  |  Strategy

Hedging toward the clinic

At first glance, last week's Hedgehog deal with Wyeth for therapeutic applications in neurology appears to leave Curis Inc.'s cupboard a bit bare. But according to President and CEO Daniel Passeri, it's all part of CRIS' plan to leverage its assets into the clinical development capabilities necessary to create its own products.

Over the last two years, CRIS has partnered out all its programs except two based on...

Read the full 335 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >